β¨ Fisheries and Health Notices
11 FEBRUARY NEW ZEALAND GAZETTE 435
Target Species
| Bycatch Species | Method(s) | Hpb 1 | Sna 8 | Sna 8 | Spo 1 | Tre 7 |
|---|---|---|---|---|---|---|
| BLL, DL, HL | BLL, DL | HL, TL | BPT, BT | BPT, BT | ||
| SN | ||||||
| Jdo 1 | - | - | - | 1.00 | 4.84 | |
| Sch 1 | 0.25 | - | - | 0.27 | 1.31 | |
| Spo 1 | - | - | - | 0.57 | - | |
| Tar 1 | - | - | - | 0.70 | - | |
| Tre 7 | - | 0.21 | - | 0.21 | 0.36 |
go1084
Health
Medicines Act 1981
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Hepatitis B immunoglobulin (Human) 100IU in 16% IgG 400IU in 16% IgG | Injection, solution | CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia | Hepatitis B Immunoglobulin |
| Ipratropium bromide monohydrate 260.9Β΅g/mL equivalent to 250Β΅g/mL ipratropium bromide | Inhalation, solution | Steripak Limited, Astmoor, Runcorn, Cheshire, England | Ipratropium Steri-Neb |
| Human Immunoglobulin G 160 mg/mL in 16% IgG | Injection, solution | CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia | Normal Immunoglobulin |
| Anti-D (Rho) immunoglobulin (Human) 250IU in 16% IgG, 625IU in 16% IgG | Injection, solution | CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia | Immunoglobulin Rh(D) |
| Flurbiprofen 8.75 mg | Lozenge | The Boots Company Plc., Beeston, Nottingham, United Kingdom | Strepfen |
| Fexofenadine hydrochloride 60 mg, pseudoephedrine hydrochloride 120 mg | Tablet, film coated | Hoechst Marion Roussel Inc., Kansas City, Missouri, United States of America | Telfast Decongestant |
| Tetanus immunoglobulin (Human) 250IU in 16% IgG | Injection, solution | CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia | Tetanus Immunoglobulin |
| Zoster immunoglobulin (Human) 100IU/mL in 16% IgG | Injection, solution | CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia | Zoster Immunoglobulin |
Dated this 5th day of February 1999.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go1077
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 19
NZLII —
NZ Gazette 1999, No 19
β¨ LLM interpretation of page content
πΎ
Fisheries (Bycatch Trade-Off) Notice (No. 1) 1999
(continued from previous page)
πΎ Primary Industries & Resources8 February 1999
Fisheries Act 1983, Bycatch Trade-Off, Quota Management, Auckland, Central East, South-East Coast, Target Species, Bycatch Species
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare5 February 1999
Medicines Act 1981, New Medicine, Distribution, Hepatitis B Immunoglobulin, Ipratropium Steri-Neb, Normal Immunoglobulin, Immunoglobulin Rh(D), Strepfen, Telfast Decongestant, Tetanus Immunoglobulin, Zoster Immunoglobulin
- G. R. Boyd, Chief Advisor, Regulation and Safety